Marcus Karl-Heinz Auth

Marcus Karl-Heinz Auth

Auto-generated profile, based on publicly available information

Marcus Karl-Heinz Auth

Paediatric Gastroenterology, Alder Hey Children’s NHS Foundation Trust, Liverpool, UK

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2012 in BMJ
Verified
Journal Article
Closed access
PDF file
MAMarcus K H Auth
Marcus K H Auth
RVRakesh Vora
Rakesh Vora
PFPaul Farrelly
Paul Farrelly
CBColin Baillie
Colin Baillie
What is childhood constipation?The term constipation describes a collection of symptoms rather than a specific disease in childhood. Diagnosis therefore relies on the reported symptoms, accurate description of bowel habits, interpretation, and examination.2 An international group has classified constipation among the spectrum of functional bowel disorders and provided a diagnostic definition.3 The definition includes reduced frequency of defecation, occurrence of faecal incontinence (soiling, encopresis), stool retention (faecal impaction), painful or hard bowel movements, or large diameter stools (box 1).Box 1 Definition of functional constipation3 5Presence of two or more of the following criteria in the previous one to two months: Two or fewer defecations in the toilet each week At least one episode of faecal incontinence each week History of retentive posturing or excessive volitional stool retention History of painful or hard bowel movements Presence of a large faecal mass in the rectum History of large diameter stools that may obstruct the toilet

29 August 2022 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
NCNeil Chanchlani
Neil Chanchlani
SLSimeng Lin
Simeng Lin
MAMarcus K. Auth
Marcus K. Auth
CLChai Leng Lee
Chai Leng Lee
HRHelena Robbins
Helena Robbins
TATariq Ahmad
Tariq Ahmad
Summary: Background: Anti‐drug antibodies are associated with treatment failure to anti‐TNF agents in patients with inflammatory bowel disease (IBD).Aim: To assess whether immunogenicity to a patient's first anti‐TNF agent would be associated with immunogenicity to the second, irrespective of drug sequenceMethods: We conducted a UK‐wide, multicentre, retrospective cohort study to report rates of immunogenicity and treatment failure of second anti‐TNF therapies in 1058 patients with IBD who underwent therapeutic drug monitoring for both infliximab and adalimumab. The primary outcome was immunogenicity to the second anti‐TNF agent, defined at any timepoint as an anti‐TNF antibody concentration ≥9 AU/ml for infliximab and ≥6 AU/ml for adalimumab.Results: In patients treated with infliximab and then adalimumab, those who developed antibodies to infliximab were more likely to develop antibodies to adalimumab, than patients who did not develop antibodies to infliximab (OR 1.99, 95%CI 1.27–3.20, p = 0.002). Similarly, in patients treated with adalimumab and then infliximab, immunogenicity to adalimumab was associated with subsequent immunogenicity to infliximab (OR 2.63, 95%CI 1.46–4.80, p < 0.001). For each 10‐fold increase in anti‐infliximab and anti‐adalimumab antibody concentration, the odds of subsequently developing antibodies to adalimumab and infliximab increased by 1.73 (95% CI 1.38–2.17, p < 0.001) and 1.99 (95%CI 1.34–2.99, p < 0.001), respectively. Patients who developed immunogenicity with undetectable drug levels to infliximab were more likely to develop immunogenicity with undetectable drug levels to adalimumab (OR 2.37, 95% CI 1.39–4.19, p < 0.001). Commencing an immunomodulator at the time of switching to the second anti‐TNF was associated with improved drug persistence in patients with immunogenic, but not pharmacodynamic failure.Conclusion: Irrespective of drug sequence, immunogenicity to the first anti‐TNF agent was associated with immunogenicity to the second, which was mitigated by the introduction of an immunomodulator in patients with immunogenic, but not pharmacodynamic treatment failure.

1 September 2020 in Gut
Verified
Journal Article
Open access
PDF file
RHRichard Hansen
Richard Hansen
SMSusanna Meade
Susanna Meade
RBR Mark Beattie
R Mark Beattie
MAMarcus Kh Auth
Marcus Kh Auth
NCNick Croft
Nick Croft
JKJochen Kammermeier
Jochen Kammermeier
Objective Paediatric acute severe colitis (ASC) management during the novel SARS-CoV-2/COVID-19 pandemic is challenging due to reliance on immunosuppression and the potential for surgery. We aimed to provide COVID-19-specific guidance using the European Crohn’s and Colitis Organisation/European Society for Paediatric Gastroenterology, Hepatology and Nutrition guidelines for comparison. Design We convened a RAND appropriateness panel comprising 14 paediatric gastroenterologists and paediatric experts in surgery, rheumatology, respiratory and infectious diseases. Panellists rated the appropriateness of interventions for ASC in the context of the COVID-19 pandemic. Results were discussed at a moderated meeting prior to a second survey. Results Panellists recommended patients with ASC have a SARS-CoV-2 swab and expedited biological screening on admission and should be isolated. A positive swab should trigger discussion with a COVID-19 specialist. Sigmoidoscopy was recommended prior to escalation to second-line therapy or colectomy. Methylprednisolone was considered appropriate first-line management in all, including those with symptomatic COVID-19. Thromboprophylaxis was also recommended in all. In patients requiring second-line therapy, infliximab was considered appropriate irrespective of SARS-CoV-2 status. Delaying colectomy due to SARS-CoV-2 infection was considered inappropriate. Corticosteroid tapering over 8–10 weeks was deemed appropriate for all. After successful corticosteroid rescue, thiopurine maintenance was rated appropriate in patients with negative SARS-CoV-2 swab and asymptomatic patients with positive swab but uncertain in symptomatic COVID-19. Conclusion Our COVID-19-specific adaptations to paediatric ASC guidelines using a RAND panel generally support existing recommendations, particularly the use of corticosteroids and escalation to infliximab, irrespective of SARS-CoV-2 status. Consideration of routine prophylactic anticoagulation was recommended.

22 March 2010 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
LHLisa Howell
Lisa Howell
ABAbdulgader Bader
Abdulgader Bader
DMDhanya Mullassery
Dhanya Mullassery
PLPaul Losty
Paul Losty
MAMarcus Auth
Marcus Auth
GKGeorge Kokai
George Kokai

5 August 2024 in Sensors
Verified
Journal Article
Open access
PDF file
RSRachael Slater
Rachael Slater
KTKukatharmini Tharmaratnam
Kukatharmini Tharmaratnam
SBSalma Belnour
Salma Belnour
MAMarcus Karl-Heinz Auth
Marcus Karl-Heinz Auth
RMRafeeq Muhammed
Rafeeq Muhammed
CPChris Probert
Chris Probert
The diagnosis of inflammatory bowel disease (IBD) in children and the need to distinguish between subtypes (Crohn’s disease (CD) and ulcerative colitis (UC)) requires lengthy investigative and invasive procedures. Non-invasive, rapid, and cost-effective tests to support these diagnoses are needed. Faecal volatile organic compounds (VOCs) are distinctive in IBD. VOC profiles can be rapidly determined using a gas chromatography–sensor device (OdoReader©). In an inception-cohort of children presenting with suspected IBD, we directly compared the diagnostic fidelity of faecal calprotectin (FCP, a non-specific protein marker of intestinal inflammation) with OdoReader© VOC profiles of children subsequently diagnosed with IBD with matched controls diagnosed with other gastrointestinal conditions. The OdoReader© was 82% (95% confidence interval 75–89%) sensitive and 71% (61–80%) specific but did not outperform FCP (sensitivity 93% (77–99%) and specificity 86% (67–96%); 250 µg/g FCP cut off) in the diagnosis of IBD from other gastrointestinal conditions when validated in a separate sample from the same cohort. However, unlike FCP and better than other similar technologies, the OdoReader© could distinguish paediatric CD from UC (up to 88% (82–93%) sensitivity and 80% (71–89%) specificity in the validation set) and justifies further validation in larger studies. A non-invasive test based on VOCs could help streamline and limit invasive investigations in children.

7 September 2021 in Pediatric and Developmental Pathology
Verified
Journal Article
Closed access
PDF file
AHAssaf Hoofien
Assaf Hoofien
SOSalvatore Oliva
Salvatore Oliva
MAMarcus Karl-Heinz Auth
Marcus Karl-Heinz Auth
EBElena Brook
Elena Brook
CGCarla Giordano
Carla Giordano
NZNoam Zevit
Noam Zevit
Background: Accurate measurements of mucosal eosinophil concentrations in gastrointestinal tracts of healthy children are necessary to differentiate health and disease states in general, and better define eosinophilic gastrointestinal diseases. Study: We retrospectively reviewed gastrointestinal biopsies from children with macroscopically normal endoscopies, who, after a minimal follow-up of one year, were not diagnosed with any organic disease. Peak eosinophil concentrations and distributions were assessed from each segment of the gastrointestinal tract. Results: Three centers (Italy, United Kingdom, and Israel) contributed 202 patients (median age 13 years IQR 9.5–15.5, range 1–18 years). Median (IQR, range) eosinophil concentrations (eos/mm2) were: esophagus 0 (0–0, 0–84), stomach 0 (0–4, 0–84), duodenal bulb 20 (13–30, 7–67), second part of duodenum 20 (13–29, 0–105), terminal ileum 29 (14–51, 0–247), cecum 53 (37–89, 10–232), ascending colon 55 (25–84, 0–236), transverse colon 38 (21–67, 4–181), descending colon 29 (17–59, 0–114), sigmoid colon 25 (13–40, 0–215) and rectum 13 (4–28, 0–152). Significant geographical variance was present, however, no differences in eosinophil concentrations were identified between children with resolving symptoms vs. those with functional diagnoses, nor across age groups. Conclusions: Standardized eosinophil concentrations from the gastrointestinal tracts of children without organic disease will serve to better define both health and disease states. No differences were found between resolved symptoms vs. functional diagnoses nor between age groups in this pediatric cohort.